Advertisement

Monitoring systemic complications of intraocular medications

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ladas ID
        • Karagiannis DA
        • Rouvas AA
        • Kotsolis AI
        • Liotsou A
        • Vergados I
        Safety of repeat intravitreal injections of bevacizu-mab versus ranibizumab: our experience after 2,000 injections.
        Retina. 2009; 29: 313-318
        • Diago T
        • McCannel CA
        • Bakri SJ
        • Pulido JS
        • Edwards AO
        • Pach JM
        Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
        Retina. 2009; 29: 601-605
        • Bakri SJ
        • McCannel CA
        • Edwards AO
        • Moshfeghi DM
        Persisent ocular hypertension following intravitreal ranibizumab.
        Graefes Arch Clin Exp Ophthalmol. 2008; 246: 955-958
        • Schmidt-Erfurth U
        Clinical safety of ranibizumab in age-related macular degeneration.
        Expert Opin Drug Saf. 2010; 9: 149-165
        • Micieli JA
        • Micieli A
        • Smith AF
        Identifying systemic safety signals following intravitreal bevacizumab: systematic reviewof the literature and the Canadian Adverse Drug Reaction Database.
        Can J Ophthalmol. 2010; 45: 231-238
        • Petrou P
        • Georgalas I
        • Giavaras G
        • et al.
        Early loss of pregnancy after intravitreal bevacizumab injection.
        Acta Ophthalmol. 2009; ([Epub ahead of print])
        • Pulido JS
        • McConnell JP
        • Lennon RJ
        • et al.
        Relationship between age-related macular degeneration-associated variants of complement factor H and LOC387715 with coronary artery disease.
        Mayo Clin Proc. 2007; 82: 301-307
        • Sun C
        • Klein R
        • Wong TY
        Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study.
        Ophthalmology. 2009; 116: 1913-1919
        • Wu Z
        • Huang J
        • Sadda S
        Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report.
        Ann Acad Med Singapore. 2010; 39: 143-145
        • Lin CJ
        • Hwang JF
        • Chen YT
        • Chen SN
        The effect of intravi-treal bevacizumab in the treatment ofCoats disease in children.
        Retina. 2010; 30: 617-622
        • Micieli JA
        • Surkont M
        • Smith AF
        A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity.
        Am J Ophthalmol. 2009; 148: 536-543.e2
        • Glade Bender JL
        • Adamson PC
        • Reid JM
        • et al.
        • Children's Oncology Group Study
        Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study.
        J ClinOncol. 2008; 26: 399-405